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Abstract
Various mammalian cells, including cancer cells, shed extracellular vesicles (EVs),
also known as exosomes and microvesicles, into surrounding tissues. These EVs
play roles in tumor growth and metastasis by promoting angiogenesis. However,
the detailed mechanism of how cancer-derived EVs elicit endothelial cell activation
remains unknown. Here, we provide evidence that early growth response-1 (Egr-1)
activation in endothelial cells is involved in the angiogenic activity of colorectal
cancer cell-derived EVs. Both RNA interference–mediated downregulation of Egr-1
and ERK1/2 or JNK inhibitor significantly blocked EV-mediated Egr-1 activation and
endothelial cell migration. Furthermore, lipid raft-mediated endocytosis inhibitor
effectively blocked endothelial Egr-1 activation and migration induced by cancer-
derived EVs. Our results suggest that Egr-1 activation in endothelial cells may be a
key mechanism involved in the angiogenic activity of cancer-derived EVs. These
findings will improve our understanding regarding the proangiogenic activities of
EVs in diverse pathological conditions including cancer, cardiovascular diseases,
and neurodegenerative diseases.
Introduction
Various types of mammalian cells, such as cancer cells, macrophages, endothelial
cells, platelets, and epithelial cells release extracellular vesicles (EVs) into their
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surroundings from the plasma and endosomal membrane compartments [1–4].
These mammalian EVs, also known as exosomes and microvesicles, are spherical
bilayered proteolipids with an average diameter of 40–250 nm and are enriched
with various bioactive constituents, including proteins, lipids, and genetic
material [1–9]. Growing evidence has revealed that EVs play pleiotropic functions
in intercellular communication: EVs stimulate recipient cells by the activation of a
receptor and the transfer of membrane proteins, signaling molecules, mRNAs, and
miRNAs [4–9].
EVs have often been referred to as ‘‘cellular dust’’, although cells shed EVs
either constitutively or in a regulated manner [1–9]. Moreover, the proteins,
mRNAs, or miRNAs in EVs differ in composition depending on the states of
donor cells [1, 4]. Recently, our group revealed that proteins of human colorectal
cancer cell-derived EVs are interconnected via physical interactions and cluster
into functional modules involved in EV biogenesis and function [4, 10].
Furthermore, the secretion of EVs is a universal cellular process occurring from
simple organisms (Archea or Gram-negative and Gram-positive bacteria) to
complex multicellular organisms, suggesting that this EV-mediated communica-
tion is evolutionarily conserved [9, 11–13]. Taken together, these findings suggest
that EVs play diverse roles in intercellular communication [6, 10]. However, the
pathophysiological roles of EVs are not completely understood.
Angiogenesis, the formation of new blood vessels from preexisting vasculature,
is a complex and multistep process involving adhesion, migration, invasion,
proliferation, and differentiation of endothelial cells [14, 15]. This neovascular-
ization occurs under various normal and pathological conditions [14]. For
example, angiogenesis is essential for tumor growth and metastasis by providing
oxygen and nutrients to the growing tumor [15]. In the tumor microenviron-
ment, a heterogeneous population of cells, including cancer cells, endothelial cells,
fibroblasts, and immune cells modulates an environment favorable to tumor
growth and invasion [16–18]. These cancer and stromal cells secrete vascular
endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF2), tumor
necrosis factor-a (TNF-a), and IL-6 into the surrounding area and these factors
contribute to tumor-associated angiogenesis [16–19].
In addition to these proangiogenic soluble factors, the cells comprising the
tumor tissue secrete EVs into the extracellular milieu and these shed EVs play
multiple roles in tumor growth and metastasis by promoting angiogenesis, tumor
invasion, and immune escape [4–8, 20–23]. After the initial report on the
angiogenic activities of EVs derived from HT1080 human fibrosarcoma and DU-
145 human prostate carcinoma cells [5], several studies confirmed that EVs
derived from cancer cells, fibroblasts, and cancer stem cells promote in vitro and
in vivo angiogenesis [4, 8, 24–28]. These angiogenic activities of EVs are mediated
by vesicular lipid(s), proteins, including receptors and tetraspanin proteins,
mRNAs, and miRNAs. However, the detailed mechanism of how EVs elicit
angiogenic activity has not been extensively studied.
Early growth response-1 (Egr-1), an immediate early gene and a zinc finger
transcription factor, plays a crucial role in angiogenesis [29–32]. In addition to
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serum exposure, Egr-1 can be rapidly and transiently induced by cytokine, growth
factor, and environmental stress, including hypoxia, fluid shear stress, and
vascular injury [33, 34]. Egr-1 regulates the expression of proangiogenic genes,
such as VEGF, FGF2, and IL-6 in endothelial cells or TNF-a in macrophages
[31, 34–36]. Within the tumor tissue, endothelial cells, cancer cells, fibroblasts,
and tumor-infiltrating macrophages can express Egr-1. Furthermore, microvessel
densities in tumor tissues obtained from Egr-1-deficient mice are lower than those
obtained from wild-type mice [37] and vessel-like structure formation in tumor
tissue was suppressed by DNAzymes that target Egr-1 mRNA [31], suggesting that
Egr-1 plays essential roles in tumor growth and angiogenesis. In this regard,
several studies have reported that Egr-1 expression in cancer cells, endothelial
cells, and macrophages is related to tumor progression [32, 36–38]. Collectively,
these findings suggest that Egr-1 plays important roles in tumor-associated
angiogenesis and tumor progression.
In this report, we provide evidence that Egr-1 activation in endothelial cells
should be a key mechanism involved in the angiogenic activity of cancer-derived
EVs. We found that Egr-1 activation by colorectal cancer cell-derived EVs
promoted endothelial cell migration via the ERK1/2 and JNK signaling pathways
and lipid raft-mediated endocytosis.
Materials and Methods
Cell culture
Human colorectal adenocarcinoma (SW480), colorectal carcinoma (HCT116),
lung adenocarcinoma (A549), and fibrosarcoma (HT1080), and normal bronchial
epithelial (BEAS-2B) cells were maintained in RPMI 1640 (Invitrogen, Carlsbad,
CA, USA) supplemented with 10% fetal bovine serum (FBS; Invitrogen), 100 U/
mL penicillin, and 0.1 mg/mL streptomycin. Human neuroblastoma (SH-SY5Y)
and prostate carcinoma (PC3) cells were maintained in MEM (Invitrogen)
supplemented with 10% FBS, 100 U/mL penicillin, and 0.1 mg/mL streptomycin.
SW480, HCT116, A549, HT1080, SH-SY5Y, PC3, and BEAS-2B were purchased
from American Type Culture Collection. Human microvascular endothelial cells
(HMEC-1s) were cultured in Endothelial Growth Medium-2 (EGM-2; Lonza,
Walkersville, MD, USA) [5]. Human umbilical vein endothelial cells (HUVECs)
were isolated from freshly delivered umbilical cords and maintained as described
previously [39]. HUVECs were cultured in medium 199 (Invitrogen) supple-
mented with 20% FBS, 3 ng/mL FGF2 (R&D Systems, Minneapolis, MN, USA),
5 U/mL heparin (Sigma-Aldrich, St Louis, MO, USA), 100 U/mL penicillin, and
0.1 mg/mL streptomycin. Cells were cultured at 37 C˚ in a humidified atmosphere
of 5% CO2. All cell lines were mycoplasma-free confirmed using e-MyCo
Mycoplasma PCR Detection Kit (iNtRON Biotechnology. Inc., Seoul, Korea).
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Purification of EVs
EVs were purified by a combination of differential centrifugation, ultrafiltration
using a 100-kDa hollow fiber membrane, ultracentrifugation onto sucrose
cushions, and iodixanol density gradient ultracentrifugation according to
previously established methods [8]. Briefly, 80–90% confluent cells were washed
twice with phosphate buffered saline and then were incubated for 24 h in serum-
free RPMI 1640 medium (SW480, HCT116, A549, HT1080, and BEAS-2B) or
serum-free MEM medium (SH-SY5Y and PC3). Approximately 2,000 mL of
conditioned medium was centrifuged at 500 g for 10 min, and then twice at
2,000 g for 15 min to eliminate cell contamination. Supernatant was further
concentrated using the QuixStand Benchtop System with a 100-kD hollow fiber
membrane (GE Healthcare, Piscataway, NJ, USA). The concentrate (,35 mL) was
placed upon 0.5 mL of 0.8 and 2.0 M sucrose cushions in buffer (20 mM HEPES,
150 mM NaCl, pH 7.4) and then centrifuged at 100,000 g for 2 h (SW 32 Ti swing
bucket rotor with a k-factor of 256.8). The EVs (0.5 mL) were harvested from the
interface between the 0.8 and 2.0 M sucrose cushions, diluted with 9 mL of
phosphate buffered saline, placed upon 0.35 mL of 0.8 M and 0.15 mL of 2.0 M
sucrose cushions, and centrifuged at 100,000 g for 2 h (SW 41 Ti swing bucket
rotor with a k-factor of 256.6). The EVs (0.5 mL) were harvested from the
interface between the 0.8 and 2.0 M sucrose cushions, and were diluted with
1.42 mL of phosphate buffered saline and 2.88 mL of 50% iodixanol (Axis-Shield
PoC AS, Nycomed, Norway), to give 30% iodixanol. This sample was placed at the
bottom of a tube and overlaid with 3 mL of 20% iodixanol and 2.5 mL of 5%
iodixanol. After centrifugation at 200,000 g for 2 h (SW 41 Ti swing bucket rotor
with a k-factor of 128.3), 10 fractions of equal volume (1 mL) were removed from
the top of the gradient. Finally, the purified EVs were measured for their protein
content using the Bradford protein assay (Bio-Rad, Munich, Germany) and
applied to further assays. We obtained 70–150 mg of EVs in total proteins from
,2,000 mL of 24 h serum-free conditioned medium of cancer cells (SW480,
HCT116, A549, HT1080, SH-SY5Y, and PC3): the yield of EVs from the same
amount of normal human bronchial epithelial cells (BEAS-2B) is ,10 mg in total
proteins.
Western blot analysis
Each fraction of iodixanol density gradients was separated by SDS-PAGE and then
transferred to a polyvinylidene difluoride membrane. The membrane was blocked
and incubated with mouse anti-CD81 (BD Biosciences, San Jose, CA), mouse
anti-CD63 antibody (Santa Cruz Biotechnology, Santa Cruz, CA), mouse anti-
GM130 antibody (BD Biosciences), and mouse anti-cytochrome c antibody (BD
Biosciences), followed by goat anti-mouse antibodies conjugated to horseradish
peroxidase (Santa Cruz Biotechnology). The immunoreactive bands were
visualized with a chemiluminnescent substrate.
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Murine Matrigel assay and immunostaining
We used 6-8 week old wild-type mice from the Jackson Laboratory. Mice (n55)
were subcutaneously injected with 0.5 mL Matrigel (BD Biosciences) containing
20 mg of SW480-derived EVs or phosphate buffered saline (Invitrogen). On day 7
after injection, the mice were killed, and the Matrigel was removed and stained for
whole-mount immunofluorescence. Blood vessels were immunostained with goat
anti-CD31 antibody (Cell Signaling Technology) followed by AlexaFluor488
donkey anti-goat antibody (Invitrogen). All images were visualized using an
FV1000 Olympus confocal microscope (Olympus, Tokyo, Japan) equipped with a
UPlanSApo 206/0.75 objective lens and acquired using FV1000-ASW 1.5
software (Olympus). The CD31-positive area (mm2) in the immunofluorescence
image was quantitatively analyzed using ImageJ software (National Institutes of
Health). All animals received humane care, and the experiments were approved by
the Institutional Animal Care and Use Committee at Pohang University of Science
and Technology, Pohang, Republic of Korea (approval number: 2011-01-0015).
Scratch wound-healing assay
HMEC-1s were plated in 24-well cell-culture plates (Corning Inc., Corning, NY)
at a density of 16105 cells per well and allowed to attach overnight. Confluent
HMEC-1s were injured by a deliberate scratch and incubated with control,
SW480-derived EVs (1 mg/mL, 0.5 mL), or EGM-2. Twelve hours after injury,
cells were washed in phosphate buffered saline, stained with CellTracker
(Invitrogen), and fixed in 4% paraformaldehyde before fluorescence imaging.
Images were visualized under an Olympus 1681 inverted fluorescence
microscope (Olympus) and acquired using MetaMorph software (Molecular
Devices, Sunnyvale, CA, USA).
Endothelial proliferation assay
HMEC-1s were plated in 24-well cell-culture plates (Corning Inc., Corning, NY)
with glass coverslips (Fisher Scientific, Rochester, NY) at a density of 56104 cells
per well and allowed to attach overnight. After a 24 h treatment with control,
SW480-derived EVs (1 mg/mL, 0.5 mL), or EGM-2, cells were fixed with 4%
paraformaldehyde and incubated with rabbit anti-phospho-histone H3 (PH3)
antibody (Upstate Biotechnology, Lake Placid, NY) followed by AlexaFluor488
goat anti-rabbit IgG antibody (Invitrogen). Nuclei were counterstained with
Hoechst (Sigma-Aldrich). Images were visualized under an FV1000 Olympus
confocal microscope (Olympus) and acquired using FV1000-ASW 3.0 software
(Olympus). The percentage of PH3-positive cells was quantified by counting the
cells with co-localized fluorescence signals.
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Real-time RT-PCR
PCR primers used in this study were designed using the Primer3 program
(Whitehead Institute, http://biotools.umassmed.edu/bioapps/primer3_www.cgi).
The primers used for gene amplification were as follows: GAPDH forward, 59-
CGAGATCCCTCCAAAATCAA-39; GAPDH reverse, 59-TTCACACCCATGA-
CGAACAT-39; EGR1 forward, 59-CCGCAGAGTCTTTTCCTGAC-39; EGR1
reverse, 59-AGCGGCCAGTATAGGTGATG-39. HMEC-1s (26105 cells) plated in
6-well cell-culture plate were treated with EVs (1 mg/mL, 2.0 mL) for 0.5, 1, 1.5, 2
and 4 h. RNA was extracted from cultured cells using the RNeasy Mini Kit
(QIAGEN, Valencia, CA, USA). For real time RT-PCR, total RNA (100 ng) was
amplified with a One Step SYBR RT-PCR Kit (TaKaRa Bio, Tokyo, Japan) using a
LightCycler 2.0 PCR system (Roche Diagnostics, Mannheim, Germany).
Amplification was carried out by heating the samples to 50 C˚ for 2 min, then at
95 C˚ for 10 min, followed by repeating cycles at 95 C˚ for 15 sec, 55 C˚ for 10 sec,
and 72 C˚ for 10 sec, for a total 45 cycles. The comparative Ct method was used for
relative quantification of target gene expression against that of a housekeeping
gene, GAPDH [40].
Egr-1 nuclear translocation
HMEC-1s were plated in 24-well cell-culture plates (Corning Inc.) with glass
coverslips (Fisher Scientific) at a density of 56104 cells per well and allowed to
attach overnight. Cells were treated with SW480-derived EVs (1 mg/mL, 0.5 mL),
fixed with 4% paraformaldehyde, and incubated with rabbit anti-Egr-1 antibody
(Cell Signaling Technology, Hitchin, United Kingdom) followed by
AlexaFluor488 goat anti-rabbit IgG antibody (Invitrogen). Nuclei were counter-
stained with Hoechst (Sigma-Aldrich). Images were visualized under an FV1000
Olympus confocal microscope (Olympus) and acquired using FV1000-ASW 3.0
software (Olympus). The percentage of Egr-1-positive cells was quantified by
counting the cells with co-localized fluorescence signals.
To investigate the effect of signaling inhibitors (BioMol Research Laboratories,
Plymouth Meeting, PA, USA) or methyl-b-cyclodextrin (MbCD; Sigma-Aldrich)
on Egr-1 nuclear translocation, HMEC-1s were treated with ERK1/2 inhibitor
(PD98059, 20 mM), p38 MAPK inhibitor (SB203580, 10 mM), JNK inhibitor
(SP600125, 20 mM), Akt inhibitor (BML-257, 20 mM), or MbCD (10 mM) in the
presence or absence of SW80-derived EVs (1 mg/mL).
RNA interference-mediated downregulation of Egr-1
Small interfering RNA (siRNA) of Egr-1 (Bioneer, Daejeon, Korea) to a final
concentration of 50 nM was transfected into HMEC-1s using Welfect-Q
(Welgene, Taegu, Korea). Non-silencing scrambled siRNA was used as the
negative control. After 48 h, cells were used for real-time RT-PCR analysis to
determine the level of Egr-1 mRNA expression, Egr-1 nuclear translocation assays,
and scratch wound-healing assays. The siRNA sequences were as follows:
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scrambled siRNA, 59-CCUACGCCACCAAUUUCGU-39; Egr-1 siRNA-1, 59-
CAGUAUCAUCUCCAUCAUA-39; Egr-1 siRNA-2, 59-AGUUUGCCAGG-
AGCGAUGA-39; Egr-1 siRNA-3, 59-GUGCAAUUGUGAGGGACAU-39.
EV uptake
SW480-derived EVs were labeled with DiI (Invitrogen) according to the
manufacturer’s instructions. Briefly, SW480-derived EVs (100 mg) were incubated
with DiI (1 mM) for 15 min at 37 C˚ and centrifuged at 100,000 g for 2 h at 4 C˚
(Type 90 Ti fixed angle rotor with a k-factor of 126.4). The pellets, DiI-labeled
EVs, were washed with phosphate buffered saline, and after ultracentrifugation at
100,000 g for 2 h at 4 C˚ (Type 90 Ti fixed angle rotor with a k-factor of 126.4),
were resuspended in phosphate buffered saline. HMEC-1s were pretreated
without or MbCD (10 mM) for 0.5 h, and then incubated with DiI-labeled
SW480-derived EVs (1 mg/mL, 0.5 mL) for 1 h. Cells were then fixed with 4%
paraformaldehyde and nuclei were stained with Hoechst (Sigma-Aldrich). Images
were visualized under an FV1000 Olympus confocal microscope (Olympus) and
acquired using FV1000-ASW 3.0 software (Olympus).
Statistical analyses
All values are expressed as means ¡ S.D. P values were calculated from one-way
or two-way analysis of variance (ANOVA) with Bonferroni correction, based on
comparisons with the appropriate control samples tested at the same time.
Results
SW480-derived EVs promote in vivo and in vitro angiogenesis
EVs released by SW480 cells were purified from culture supernatants by a
combination of differential centrifugation, ultrafiltration using a 100-kDa hollow
fiber membrane, ultracentrifugation onto sucrose cushions, and iodixanol density
gradients as reported [8]. Consistent with the previous study [8], the purified EVs
had a density of,1.098 g/mL and harbored CD81 and CD63, EV marker proteins
(Fig. 1A). However, these purified EVs did not contain GM130 (a cis-Golgi
protein) and cytochrome c (a mitochondrial protein found in apoptotic bodies):
these two proteins are well-known non-vesicular proteins (Fig. 1B). We first
showed that EVs derived from SW480 human colorectal adenocarcinoma cells
induced in vivo neovascularization (Fig. 1C and 1D). When SW480-derived EVs
within Matrigel were injected subcutaneously into mice, a massive formation of
CD31-positive vessel-like structures was observed (Fig. 1C). In contrast, no
apparent vessel formation was detected in the Matrigel without EVs. EVs
significantly induced a 10.4-fold increase in the CD31-positive area in Matrigel
when compared with the untreated control (Fig. 1D).
We next investigated the proangiogenic activity of SW480-derived EVs on
human endothelial cells, HMEC-1s in vitro. Scratch wound-healing assays revealed
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that EVs induced a 4.1-fold increase in the number of migrated endothelial cells
into the denuded zone compared with the untreated control (Fig. 1E).
Furthermore, EVs potently stimulated the proliferation of endothelial cells: the
percentage of PH3-positive cells increased 8.9-fold over that of the unstimulated
cells (Fig. 1F). The positive control, EGM-2 supplemented with diverse
angiogenic factors such as EGF, FGF2, VEGF, and IGF1, also induced both
endothelial cell migration and proliferation. The migratory and proliferative
activities of SW480-derived EVs were also observed in other endothelial cells,
HUVECs (data not shown). Therefore, our data indicate that SW480-derived EVs
have in vivo and in vitro angiogenic activities.
Fig. 1. In vivo and in vitro angiogenesis induced by SW480-derived EVs. (A, B) EVs released by SW480 cells were purified from culture supernatants by
a combination of differential centrifugation, ultracentrifugation onto sucrose cushions, and iodixanol density gradients. Each fraction of iodixanol density
gradients was analyzed by Western blotting to detect CD81 and CD63, marker proteins of EVs (A). The purified EVs in fraction 3 were analyzed by Western
blotting to detect non-EV marker proteins (GM130 and cytochrome c). SW480-derived whole cell lysate (WCL; 10 mg) and SW480-derived EVs (EVs; 10 mg)
were loaded for Western blotting analysis (B). (C, D) Matrigel in the presence or absence of SW480-derived EVs (20 mg) was injected subcutaneously into
C57BL/6 mice. After 7 days, whole-mount staining of Matrigel with anti-CD31 antibody was conducted (n55). Representative confocal Z-stack photographs
of whole mounts stained for CD31 (green) are shown in panel C. Scale bars represent 100 mm. Fluorescence intensities of CD31 staining of the Z-stack
plane of the Matrigel were measured as described in the Methods (D). (E) Migratory activity of SW480-derived EVs was evaluated by a scratch wound-
healing assay. Confluent HMEC-1s were scratched and treated with SW480-derived EVs (1 mg/mL); then the number of migrated cells in the denuded zone
was evaluated after 12 h (n53). (F) Proliferative activity of SW480-derived EVs (1 mg/mL) was evaluated by assessing the mitosis marker PH3. After 24 h,
the PH3 and nuclei were stained with anti-PH3 antibody and Hoechst, respectively and evaluated by confocal microscopy. The percentage of PH3-positive
cells in HMEC-1s was quantified by counting the cells with co-localized fluorescence signals (n53). As a positive control, HMEC-1s were treated with EGM-
2 medium supplemented with diverse angiogenic factors such as EGF, FGF2, VEGF, and IGF1. Data are represented as mean ¡ SD. *, P,0.05; **,
P,0.01; ***, P,0.001; n.s., not significant.
doi:10.1371/journal.pone.0115170.g001
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SW480-derived EVs induce Egr-1 activation in endothelial cells
Egr-1 plays a crucial role in tumor-associated angiogenesis [29–32]. We thus
examined the possibility of activation of endothelial Egr-1 by SW480-derived EVs
(Fig. 2). Real time RT-PCR analyses revealed that treatment with SW480-derived
EVs caused rapid and transient elevation of Egr-1 expression at the transcriptional
level in human endothelial cells, HMEC-1s and HUVECs (Fig. 2A). We used
HMEC-1s in the following experiments. Moreover, EVs from other human cancer
cells (HCT116 colorectal carcinoma, A549 lung adenocarcinoma, HT1080
fibrosarcoma, PC3 prostate carcinoma, and SH-SY5Y neuroblastoma) also
induced Egr-1 mRNA expression in human endothelial cells, whereas EVs from
normal human bronchial epithelial cells (BEAS-2B) did not (Fig. 2B). We further
investigated Egr-1 activation after stimulation by SW480-derived EVs. EVs
induced rapid and transient expression and nuclear translocation of Egr-1 protein
in HMEC-1s; the maximum effect was observed at 1 h after EV treatment (Fig. 2C
and 2D). Taken together, cancer-derived EVs induce Egr-1 activation by
increasing its expression and nuclear translocation in endothelial cells. These
observations suggest that Egr-1 activation might be critical for modulating EV-
induced angiogenesis.
Egr-1 siRNA attenuates endothelial cell migration induced by
SW480-derived EVs
We next investigated the role of Egr-1 in EV-induced endothelial cell migration
using siRNA. When we examined three Egr-1 siRNAs, we found that Egr-1
siRNA-1 most effectively reduced the Egr-1 mRNA level in endothelial cells but
scrambled siRNA did not shown this inhibitory effect (Fig. 3A). Endothelial cells
treated with Egr-1 siRNA-1 efficiently blocked EV-induced Egr-1 activation
(Fig. 3B) and migration as observed in scratch wound-healing assays (Fig. 3C and
3D) while scrambled siRNA did not show these inhibitory effects. Thus, our
results indicated that EV-induced expression and nuclear translocation of Egr-1 in
endothelial cells should contribute to EV-induced endothelial cell migration.
ERK1/2 and JNK signaling pathways are involved in EV-induced
Egr-1 activation and migration in endothelial cells
We next investigated the signaling pathways involved in EV-mediated Egr-1
activation. ERK1/2 inhibitor (PD98059) and JNK inhibitor (SP600125) almost
completely suppressed Egr-1 nuclear translocation in endothelial cells after
stimulation with SW480-derived EVs, but p38 MAPK inhibitor (SB203580) and
Akt inhibitor (BML-257) had no effect (Fig. 4A and 4B). Moreover, we observed
that PD98059 and SP600125 treatments almost completely blocked EV-induced
endothelial cell migration while these inhibitors showed no apparent effect on the
basal migration of endothelial cells (Fig. 4C and 4D). Furthermore, PD98059 or
SP600125 almost completely inhibited the in vivo angiogenic activities of SW480-
derived EVs (Fig. 4E and 4F). All these observations indicated that the ERK1/2
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and JNK signaling pathways are essential for Egr-1 activation, endothelial cell
migration, and in vivo angiogenesis.
Endocytosis inhibitor inhibits Egr-1 activation and endothelial cell
migration induced by SW480-derived EVs
As a potential involvement of lipid raft endocytosis in EV uptake [41, 42], we
examined the role of the lipid rafts in EV uptake by endothelial cells. DiI-labeled
EV uptake was significantly inhibited following treatment with MbCD (10 mM)
(Fig. 5A). EV-induced endothelial cell migration into denuded zone was
completely blocked by MbCD treatment (Fig. 5B). Moreover, endothelial cells
Fig. 2. Egr-1 activation in endothelial cells by SW480-derived EVs. (A) HMEC-1s and HUVECs were incubated with SW480-derived EVs (1 mg/mL) or
untreated control. mRNA was isolated from untreated control cells or cells treated with EVs for 0, 0.5, 1, 2, and 4 h and analyzed using real time RT-PCR
(n53). Values represent Egr-1 mRNA/GAPDH mRNA normalized to untreated control cells. (B) HMEC-1s were treated with EVs (1 mg/mL) derived from
HCT116 colorectal carcinoma, A549 lung adenocarcinoma, HT1080 fibrosarcoma, PC3 prostate carcinoma, SH-SY5Y neuroblastoma, and BEAS-2B
normal bronchial epithelial cells for 0.5 h (n53). (C, D) In HMEC-1s, nuclear translocation of Egr-1 protein after stimulation with SW480-derived EVs (1 mg/
mL) for 0.5, 1, 2, and 4 h was analyzed under confocal microscopy (n53). Nuclei and Egr-1 proteins were stained with Hoechst (blue) and anti-Egr-1
antibody (red), respectively. Co-localized fluorescence signals (purple) indicate the translocation of Egr-1 into the nucleus. Representative photographs are
shown in panel C. Scale bars represent 30 mm. The percentage of Egr-1-positive nuclei was determined by measuring the number of cells with nucleus
colocalized signals over that of total cells (D). Data are represented as mean ¡ SD. *P,0.05; **P,0.01; **P,0.001; n.s., not significant.
doi:10.1371/journal.pone.0115170.g002
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treated with MbCD completely blocked EV-induced Egr-1 activation (Fig. 5C and
5D). Thus, our results indicated that EV uptake via lipid rafts contributes to Egr-1
activation and migration in endothelial cells.
Discussion
Although cancer-derived EVs play a pivotal role in tumor growth and metastasis
by promoting angiogenesis [4–8, 24–27], the detailed mechanism of how cancer-
derived EVs elicit endothelial cell activation is not completely understood. In the
present study, we provide evidence that Egr-1 activation in endothelial cells is a
key mechanism involved in the angiogenic activities of cancer-derived EVs. More
specifically, we showed that: (1) SW480-derived EVs promoted in vivo and in vitro
Fig. 3. Inhibition of Egr-1 activation and endothelial cell migration by Egr-1 siRNA. (A) HMEC-1s were transfected with 50 nM of scrambled siRNA or
Egr-1 siRNA-1, Egr-1 siRNA-2, or Egr-1 siRNA-3. mRNAs were isolated from the cells after 48 h and the level of Egr-1 mRNA was analyzed using real time
RT-PCR (n53). (B) Nuclear translocation of Egr-1 protein after stimulation with SW480-derived EVs (1 mg/mL) for 1 h was analyzed in scrambled siRNA
(50 nM) or Egr-1 siRNA-1 (50 nM) transfected HMEC-1s (n53). (C, D) Confluent HMEC-1s transfected with scrambled siRNA (50 nM) or Egr-1 siRNA-1
(50 nM) were scratched and treated with SW480-derived EVs (1 mg/mL); then the number of migrated cells in the denuded zone was evaluated after 12 h
(n53). The number of migrated cells in the denuded zone of each group is shown in panel D. Scale bars represent 100 mm. Data are represented as mean
¡ SD. *P,0.05; **P,0.01; *** P,0.001; n.s., not significant.
doi:10.1371/journal.pone.0115170.g003
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Fig. 4. Role of ERK1/2 and JNK signaling pathways in SW480-derived EV-mediated endothelial cell migration. (A, B) HMEC-1s were pretreated with
signaling inhibitors for 1 h and then stimulated for 1 h with SW480-derived EVs (1 mg/mL). Nuclear translocation of Egr-1 protein was analyzed using
confocal microscopy (n53). Nuclei and Egr-1 proteins were stained with Hoechst (blue) and anti-Egr-1 antibody (red), respectively. Co-localized
fluorescence signals (purple) indicate the translocation of Egr-1 into the nucleus. Representative photographs are shown in panel A. The percentage of Egr-
1-positive nuclei was determined by measuring the number of cells with nucleus colocalized signals over total cells (B). (C, D) Confluent HMEC-1s were
scratched and treated with SW480-derived EVs (1 mg/mL) in the presence or absence of signaling inhibitors; then the number of migrated cells in the
Egr-1 Activation by Extracellular Vesicles
PLOS ONE | DOI:10.1371/journal.pone.0115170 December 12, 2014 12 / 18
angiogenesis; (2) SW480-derived EVs induced Egr-1 activation by increasing its
expression and nuclear translocation in endothelial cells; (3) EVs from other
human cancer cells also induced Egr-1 expression in endothelial cells; (4) siRNA-
denuded zone was evaluated after 12 h (n53). Representative photographs of confocal microscopic imaging are shown in panel C and the number of
migrated cells in the denuded zone of each group is shown in panel D. ERK1/2 inhibitor, PD98059 (20 mM); p38 MAPK inhibitor, SB203580 (10 mM); JNK
inhibitor, SP600125 (20 mM); Akt inhibitor, BML-257 (20 mM). (E, F) C57BL/6 mice were subcutaneously injected with Matrigel containing SW480-derived
EVs (20 mg) with PD98059 (20 mM) or SP600125 (20 mM). After 7 days, whole-mount staining of Matrigel with anti-CD31 antibody was conducted (n55).
Representative confocal Z-stack photographs of whole mounts stained for CD31 (green) are shown in panel E. Fluorescence intensities of CD31 in the Z-
stack plane of the Matrigel were measured as described in the Methods (F). Scale bars in panels A, C, and E represent 30, 100, and 100 mm, respectively.
Data are represented as mean ¡ SD. ***P,0.001.
doi:10.1371/journal.pone.0115170.g004
Fig. 5. Inhibition of Egr-1 activation and endothelial cell migration by MbCD. (A) HMEC-1s were treated with DiI-labeled SW480-derived EVs (1 mg/mL)
for 1 h in the presence or absence of MbCD (10 mM) (n53). SW480-derived EVs and nuclei were stained with DiI (red) and Hoechst (blue) respectively.
Representative photographs are shown in panel A. Scale bars represent 10 mm. (B) Confluent HMEC-1s were scratched and treated with SW480-derived
EVs (1 mg/mL) in the presence or absence of MbCD (10 mM); then the number of migrated cells in the denuded zone was evaluated after 12 h (n53). (C, D)
HMEC-1s were pretreated with MbCD (10 mM) for 1 h and then stimulated with SW480-derived EVs (1 mg/mL) for 1 h. Scale bars represent 30 mm. Nuclear
translocation of Egr-1 protein was analyzed using confocal microscopy and the percentage of Egr-1-positive nuclei was determined by measuring the
number of cells with nucleus co-localized signals over that of total cells (n53). Data are represented as mean ¡ SD. ***P,0.001.
doi:10.1371/journal.pone.0115170.g005
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mediated downregulation of Egr-1 and treatment with ERK1/2 or JNK inhibitor
suppressed both EV-mediated Egr-1 activation and endothelial cell migration; and
(5) Lipid raft-mediated endocytosis inhibitor, MbCD effectively inhibited
endothelial Egr-1 activation and migration induced by SW480-derived EVs. Taken
together, these data indicate that Egr-1 activation in endothelial cells is a crucial
mechanism involved in cancer-derived EV-induced angiogenesis.
Egr-1 is a rapidly and transiently inducible gene by diverse stimuli, including
growth factors, cytokines, and environmental stresses [29–32]. Transient Egr-1
expression patterns are observed in diverse Egr-1 producing cells such as
endothelial cells, macrophages, and fibroblasts. For example, TNF-a and VEGF
induced transient Egr-1 activation in HUVECs, with a maximum at 1 h and
dropped to basal levels within 4 h [43]. However, sustained expression of Egr-1
suppresses tumor growth and neovascularization [32]. Sustained Egr-1 expression
in endothelial cells led to strong upregulation of the corepressor NAB2 and other
genes involved in anti-angiogenesis, growth arrest, and apoptosis [32]. Therefore,
rapid and transient Egr-1 gene expression is crucial for tumor-associated
angiogenesis and tumor progression.
In the present study, we observed that EVs derived from SW480 human
colorectal cancer cells are Egr-1-inducible stimuli in endothelial cells, HMEC-1s
and HUVECs. Egr-1 gene expression in these cells was transiently induced with
maximal levels at 0.5–1.5 h and decreased to basal levels at 4 h after stimulation
with SW480-derived EVs. Moreover, we showed that siRNA-mediated down-
regulation of Egr-1 significantly blocked EV-mediated endothelial cell migration
by inhibiting EV-induced Egr-1 activation. Thus, rapid and transient regulation of
Egr-1 expression and activation after stimulation with cancer-derived EVs should
contribute to EV-induced endothelial cell activation and in vitro angiogenesis.
However, further studies on Egr-1 knockout mice [44, 45] should be carried out
to understand the exact role of endothelial Egr-1 during cancer EV-induced
neovascularization. In addition, we found that endothelial Egr-1 expression can
also be induced by EVs from other human cancer cells (HCT116 colorectal
carcinoma, A549 lung adenocarcinoma, PC3 prostate carcinoma, HT1080
fibrosarcoma, and SH-SY5Y neuroblastoma) but not by normal human bronchial
epithelial BEAS-2B cell-derived EVs. Although further study is required, we can
speculate that Egr-1 expression in endothelial cells is a specific process regulated
by cancer-derived EVs rather than a general phenomenon.
Recently, EVs were reported to harbor mRNAs that can be transferred to and
function in the recipient cells by translation of vesicular mRNAs into proteins
[7, 8]. Our previous study showed that SW480-derived EVs harbor 11,327
mRNAs: cell cycle-related mRNAs belonging to the M-phase are specifically
enriched [8]. A further examination of our previous study, Egr-1 mRNA is also
present in SW480-derived EVs. By quantitative real-time RT-PCR analysis, we
found that the amount of Egr-1 mRNA present in 1 mg of EVs was equivalent to
that of 5,800¡500 HMEC-1s. Note that treatment with 2.0 mg of EVs to 2.06105
HMEC-1s in 2.0 mL culture medium caused the maximum 4.5- to 6.0-fold
increase in Egr-1 mRNA levels compared with untreated controls: the amount of
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Egr-1 mRNA present in untreated control cells is about 17 times more than that of
EVs. If we assume that all added EVs were internalized by cultured cells, a single
HMEC-1 cell uptakes less than 10 pg of EVs in total protein amount and one
seventeenth of Egr-1 mRNA molecules present in the untreated control cells.
Thus, most of the Egr-1 mRNA increase in EV-treated endothelial cells should be
due to the induction of Egr-1 expression at the transcriptional level rather than
the transfer of vesicular Egr-1 transcripts to the cells. Although we do not know
the local concentration of EVs in tumor tissues, the concentration of EVs in serum
of cancer patients has been reported to be 1,000 mg/mL [46]. We can speculate
that the local EV concentration in the tumor microenvironment would be higher
than that in the serum, suggesting that EV dose used in this study (1 mg/mL) is
patho-physiologically possible. Further study to determine the concentration of
EVs in tumor tissues and to quantitate how many EVs are delivered to the target
cell may help us understand the role of cancer EVs in tumor-associated
angiogenesis.
In the present study, we demonstrated that siRNA-mediated downregulation of
Egr-1 blocked EV-mediated Egr-1 activation and endothelial cell migration.
Further dissection of the signaling pathways involving a pharmacologic approach
revealed that ERK1/2 and JNK MAPKs, but not p38 MAPK or Akt pathways were
crucial in the EV-mediated Egr-1 activation in endothelial cells. In agreement with
our findings, the requirement of ERK1/2 and JNK activation for Egr-1 activation
was also reported in cocaine-treated human endothelial cells [47] and FGF2-
treated astrocytes [48]. Moreover, we observed that blockage of the ERK1/2 or
JNK signaling pathway almost completely blocked EV-induced endothelial cell
migration. Thus, our findings suggest that Egr-1 is a crucial proangiogenic
transcription factor triggered by cancer-derived EVs and that ERK1/2 and JNK are
upstream signaling pathways involved in EV-mediated endothelial Egr-1
activation. However, we could not completely exclude the possibility that other
transcription factor(s) could be triggered by the ERK1/2 or JNK signal pathway.
In the future, systemic analysis on EV-induced signaling pathways and
transcriptional alternations should be conducted to identify the pivotal effectors
in EV-induced angiogenesis comprehensively.
In summary, our study has revealed that Egr-1 activation in endothelial cells is a
crucial mechanism of cancer-derived EV-induced angiogenesis. In addition, we
showed that EV-mediated endothelial Egr-1 activation and migration were
mediated by ERK1/2 or JNK signaling pathway and lipid raft-mediated
endocytosis. Our findings improve our understanding regarding the angiogenic
activities of cancer-derived EVs in the tumor microenvironment.
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